GlassScriptPhysician profile
Thomas Ray Cooke
NPI 1255427902
$7,242.65
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $1,243 · 2021: $1,843 · 2022: $1,299 · 2023: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $952.92 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $825.64 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $746.89 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $664.37 | 2019-2023 | |
| Lilly USA, LLC | $615.06 | 2019-2023 | Mounjaro, Emgality, Reyvow |
| Novo Nordisk INC | $473.83 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $424.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $357.61 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $345.34 | 2019-2022 | |
| Allergan, INC. | $229.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $227.84 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.33 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $147.99 | 2020-2023 | Eliquis |
| Astellas Pharma US INC | $145.10 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.95 | 2020-2023 | Xifaxan, Trulance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $93.42 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.11 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.89 | 2019-2022 | |
| Lundbeck LLC | $67.84 | 2023 | Rexulti |
| Abbott Laboratories | $66.26 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $57.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $56.63 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $48.28 | 2019-2023 | Qelbree |
| Biodelivery Sciences International, INC. | $31.96 | 2019-2021 | |
| Sanofi Pasteur INC. | $29.53 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $24.28 | 2023 | Dupixent |
| Amarin Pharma, INC. | $23.28 | 2020 | |
| Nevro Corp. | $22.11 | 2021 | |
| Dexcom, INC. | $21.70 | 2021 | |
| Exact Sciences Corporation | $21.40 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $21.35 | 2023 | Sunosi |
| Eisai INC. | $14.89 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.06 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.70 | 2020 | |
| Philips North America LLC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cooke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.